1 brand tagged as Tyrosine Kinase Inhibitor. Discover which parent companies own these brands.
Owned by Novartis
Prescription oncology drug (nilotinib) for chronic myeloid leukemia, owned by Novartis AG. Generic versions launched in 2025.